These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 7631520)

  • 1. In vivo CTL induction with point-substituted ovalbumin peptides: immunogenicity correlates with peptide-induced MHC class I stability.
    Lipford GB; Bauer S; Wagner H; Heeg K
    Vaccine; 1995 Feb; 13(3):313-20. PubMed ID: 7631520
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Primary in vivo responses to ovalbumin. Probing the predictive value of the Kb binding motif.
    Lipford GB; Hoffman M; Wagner H; Heeg K
    J Immunol; 1993 Feb; 150(4):1212-22. PubMed ID: 7679422
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Presentation of a horse cytochrome c peptide by multiple H-2b class I major histocompatibility complex (MHC) molecules to C57BL/6- and bm1-derived cytotoxic T lymphocytes: presence of a single MHC anchor residue may confer efficient peptide-specific CTL recognition.
    Sheil JM; Schell TD; Shepherd SE; Klimo GF; Kioschos JM; Paterson Y
    Eur J Immunol; 1994 Sep; 24(9):2141-9. PubMed ID: 7522163
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of mutations in the MHC class I peptide binding groove on the cytotoxic T lymphocyte recognition of the Kb-restricted ovalbumin determinant.
    Nikolić-Zugić J; Carbone FR
    Eur J Immunol; 1990 Nov; 20(11):2431-7. PubMed ID: 2253683
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficient MHC class I-peptide binding is required but does not ensure MHC class I-restricted immunogenicity.
    Feltkamp MC; Vierboom MP; Kast WM; Melief CJ
    Mol Immunol; 1994 Dec; 31(18):1391-401. PubMed ID: 7823965
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dissection of major histocompatibility complex (MHC) and T cell receptor contact residues in a Kb-restricted ovalbumin peptide and an assessment of the predictive power of MHC-binding motifs.
    Jameson SC; Bevan MJ
    Eur J Immunol; 1992 Oct; 22(10):2663-7. PubMed ID: 1396971
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Determinant selection of major histocompatibility complex class I-restricted antigenic peptides is explained by class I-peptide affinity and is strongly influenced by nondominant anchor residues.
    Chen W; Khilko S; Fecondo J; Margulies DH; McCluskey J
    J Exp Med; 1994 Oct; 180(4):1471-83. PubMed ID: 7523572
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of T-cell responses to peptides and lipopeptides with MHC class I binding motifs derived from the amino acid sequence of the 19-kDa lipoprotein of Mycobacterium tuberculosis.
    Fonseca DP; Joosten D; Snippe H; Verheul AF
    Mol Immunol; 2000 Jun; 37(8):413-22. PubMed ID: 11090876
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design of agonistic altered peptides for the robust induction of CTL directed towards H-2Db in complex with the melanoma-associated epitope gp100.
    van Stipdonk MJ; Badia-Martinez D; Sluijter M; Offringa R; van Hall T; Achour A
    Cancer Res; 2009 Oct; 69(19):7784-92. PubMed ID: 19789338
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Peptide engineering allows cytotoxic T-cell vaccination against human papilloma virus tumour antigen, E6.
    Lipford GB; Bauer S; Wagner H; Heeg K
    Immunology; 1995 Feb; 84(2):298-303. PubMed ID: 7751006
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A viral peptide can mimic an endogenous peptide for allorecognition of a major histocompatibility complex class I product.
    Guimezanes A; Schumacher TN; Ploegh HL; Schmitt-Verhulst AM
    Eur J Immunol; 1992 Jun; 22(6):1651-4. PubMed ID: 1318201
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Can one predict antigenic peptides for MHC class I-restricted cytotoxic T lymphocytes useful for vaccination?
    Calin-Laurens V; Trescol-Biémont MC; Gerlier D; Rabourdin-Combe C
    Vaccine; 1993; 11(9):974-8. PubMed ID: 7692684
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Induction of ovalbumin-specific cytotoxic T cells by in vivo peptide immunization.
    Carbone FR; Bevan MJ
    J Exp Med; 1989 Mar; 169(3):603-12. PubMed ID: 2784478
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro priming of cytotoxic T lymphocytes against poorly immunogenic epitopes by engineered antigen-presenting cells.
    Bellone M; Iezzi G; Manfredi AA; Protti MP; Dellabona P; Casorati G; Rugarli C
    Eur J Immunol; 1994 Nov; 24(11):2691-8. PubMed ID: 7525300
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cytotoxic T-cells specific for natural IgE peptides downregulate IgE production.
    Chen SS; Gong J; Yang YM; Oettgen H; Zanetti M
    Cell Immunol; 2005 Jan; 233(1):11-22. PubMed ID: 15913585
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Peptide loading of empty major histocompatibility complex molecules on RMA-S cells allows the induction of primary cytotoxic T lymphocyte responses.
    De Bruijn ML; Schumacher TN; Nieland JD; Ploegh HL; Kast WM; Melief CJ
    Eur J Immunol; 1991 Dec; 21(12):2963-70. PubMed ID: 1660811
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Peptide affinity for MHC influences the phenotype of CD8(+) T cells primed in vivo.
    Ma H; Kapp JA
    Cell Immunol; 2001 Nov; 214(1):89-96. PubMed ID: 11902833
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A 16-mer peptide (RQIKIWFQNRRMKWKK) from antennapedia preferentially targets the Class I pathway.
    Pietersz GA; Li W; Apostolopoulos V
    Vaccine; 2001 Jan; 19(11-12):1397-405. PubMed ID: 11163662
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Priming of class I-restricted cytotoxic T lymphocytes by vaccination with recombinant protein antigens.
    Schirmbeck R; Deml L; Melber K; Wolf H; Wagner R; Reimann J
    Vaccine; 1995 Jun; 13(9):857-65. PubMed ID: 7483809
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differential binding of a minor histocompatibility antigen peptide to H-2 class I molecules correlates with immune responsiveness.
    Wettstein PJ; van Bleek GM; Nathenson SG
    J Immunol; 1993 Apr; 150(7):2753-60. PubMed ID: 7681080
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.